# Ascent Biomedical Ventures

> Ascent Biomedical Ventures is a VC fund backing Health Care and Biotechnology. See 19 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 19
- Last investment: Nov 2019
- Lead investor: 26%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/ascent-biomedical-ventures/about/
- Website: http://www.abvlp.com

Ascent Biomedical Ventures is a financial organisation which is interested in investing in seed and early-stage biomedical technology companies developing medical devices, biopharmaceuticals, healthcare services, and information technology. Their investments are concentrated in the USA.

## Contacts

5 contacts available for Ascent Biomedical Ventures. Shizune tracks 8 team members at Ascent Biomedical Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ascent-biomedical-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 47% |
| Biotechnology | 7 | 37% |
| Therapeutics | 4 | 21% |
| Medical | 3 | 16% |
| Medical Device | 3 | 16% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 26% |
| Funding Round | 4 | 21% |
| Series A | 3 | 16% |
| Series C | 2 | 11% |
| Seed | 1 | 5% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 12 | 63% |
| Israel | 1 | 5% |
| Switzerland | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andrew J. Carter | President | 0 | https://shizune.co/investors/profile/andrew-j-carter |
| Avi Kometz | Partner | 3 | https://shizune.co/investors/profile/avi-kometz |
| Barry Kurokawa | Managing Director | 0 | https://shizune.co/investors/profile/barry-kurokawa |
| Douglas A. P. Hamilton | Special Limited Partner | 0 | https://shizune.co/investors/profile/douglas-a-p-hamilton |
| Geoffrey W. Smith | Founder and Managing Partner | 20 | https://shizune.co/investors/profile/geoffrey-w-smith |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Peerbridge Health | Peerbridge Health is a mobile health IT company that seeks to bring independence and precision with remote monitoring capabilities for medical, wellness, and performance-based needs including the monitoring of vital signs, with thoughtful design and a seamless user experience. It has two digital health and fitness pioneering patents formedical-grade monitoring of all vital signs, with other patents pending.The company was founded by Angelo Acquista and is based in New York. | $11M |  | Nov 19, 2019 |  |
| Motus GI | Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System to improve the colonoscopy experience and assist in the early detectionand prevention of colorectal cancer and other diseases of the rectum and colon. | $30M |  | Dec 01, 2016 |  |
| CuraSeal Inc. | CuraSeal provides regenerating medical technology solutions to restore structure and function of damaged tissues and organs. | $3.3M | Seed | May 01, 2015 |  |
| eCaring Home Care Software | eCaring Home Care Software offers Home Care Agencies a SaaS solution for scheduling, delivering, and billing home care services. We also offer mobile apps with Electronic Visit Verification (EVV) to support the delivery of home care services and secure communications for nurses and caregivers. | $3.5M | Series A | Apr 16, 2014 |  |
| Covagen | Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architecturesto maximize efficacy.Their goal is to access novel biology for each product candidate. Covagen’s lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis.In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL.Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagen’s drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures. | $68.7M | Series B | Dec 09, 2013 |  |
| Xlumena | Xlumena develops image-guided therapeutic endoscopy products. It develops Bile Duct Stenting, a self-expanding anchor stent and precision XL delivery system. The company also develops Pseudocyst Drainage, an integrated XF system designed to enable reliable pseudocyst drainage; and Hiatal Hernia Repair that enables the repair of a hiatal hernia frominside the GI lumen.Xlumena was founded in 2007 and is based in Mountain View, California. | $25M | Series C | Dec 03, 2013 |  |
| Coferon | Coferon is a biotechnology company that employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells. The Company is based at the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York. | $12M | Series B | Jul 16, 2012 |  |
| Cara Therapeutics | Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patentedcompound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology. | $4.8M | Series D | May 21, 2012 |  |
| Xlumena | Xlumena develops image-guided therapeutic endoscopy products. It develops Bile Duct Stenting, a self-expanding anchor stent and precision XL delivery system. The company also develops Pseudocyst Drainage, an integrated XF system designed to enable reliable pseudocyst drainage; and Hiatal Hernia Repair that enables the repair of a hiatal hernia frominside the GI lumen.Xlumena was founded in 2007 and is based in Mountain View, California. | $7M | Series B | Apr 29, 2011 |  |
| Cara Therapeutics | Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patentedcompound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology. | $15M | Series D | Jul 21, 2010 |  |

10 of 19 investments shown.

## Co-investors
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 3 deals together
- [Devon Park BioVentures](https://shizune.co/investors/profile/devon-park-bioventures) — VC Fund, 3 deals together
- [MVM Life Science Partners](https://shizune.co/investors/profile/mvm-life-science-partners) — VC Fund, 3 deals together
- [Scottish Widows Investment Partnership](https://shizune.co/investors/profile/scottish-widows-investment-partnership) — VC Fund, 3 deals together
- [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 2 deals together
- [Charter Life Sciences](https://shizune.co/investors/profile/charter-life-sciences) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Ascent Biomedical Ventures invest in?

Ascent Biomedical Ventures invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series B and Funding Round stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Ascent Biomedical Ventures?

Public channels for Ascent Biomedical Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Ascent Biomedical Ventures?

The team at Ascent Biomedical Ventures includes Andrew J. Carter (President), Avi Kometz (Partner) and Barry Kurokawa (Managing Director), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co